Injecting extracellular vesicles from healthy mice into mice that had an MS-like disease resulted in the development of a relapse-remitting disease and active CD8+ cells, similar to that seen in human patients with multiple sclerosis. Examining the EVs in mice and humans with MS, researchers identified they contained fibrinogen, a protein normally associated with blood clotting and wound healing. According to researchers, the EVs with fibrinogen appear to activate the CD8+ immune cells. The findings could help with the development of new treatments for RRMS.
Obesity and a higher body mass index negatively impacts the progression of Multiple Sclerosis. Ceramides are more abundant in the blood of those who are overweight. The ceramides enter inside the nucleus of monocytes, causing proliferation. The increased number of monocytes travel back to the brain, causing more damage for those with RRMS.
Researchers reveal that a year after receiving autologous haematopoietic stem cell transplantation for relapse remitting multiple sclerosis, almost all of the patients showed no signs of the disease and the level of their disability was significantly improved.
A new Nature Communications study reports the antidepressant Clomipramine may relieve symptoms of primary progressive multiple sclerosis.
Researchers have identified a unique biomarker in the blood of people with Multiple Sclerosis. Using a simple blood test, researchers were able to identify those with MS and discriminate between people at different stages of the disease.
Researchers report resistance training may slow down the progression of multiple sclerosis by protecting the nervous system against the disease.
Researchers detail possible adverse reactions, from stroke to depression, for a common medication given to help treat multiple sclerosis.
FDA approves a new drug to treat both relapsing-remitting multiple sclerosis and primary progressive MS.
A new study reveals immunosupressive therapy coupled with stem cell transplantation can induce sustained remission in RRMS patients.
Clinical trials show that a new drug called ocrelizumab can reduce attacks in people with RRMS, and can reduce new symptom development in patients with primary progressive multiple sclerosis.
According to researchers, a drug used to treat multiple sclerosis could help to reverse some of the physical disabilities associated with the disease.
According to a new study, an insufficient amount of good bacteria could have a direct link to MS.